PharmAbcine Inc banner

Intrinsic Value

Not Available for PharmAbcine Inc

There is not enough data to reliably calculate the intrinsic value for PharmAbcine Inc.

Do our valuations actually work? See backtest results .

Alternatives to PharmAbcine Inc

Fundamental Analysis

What PharmAbcine Does

Biotechnology Health Care

PharmAbcine Inc. engages in the development of human therapeutic monoclonal antibody (mAb) for the treatment of cancer and inflammatory diseases. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2018-11-21. The firm researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Company’s major products include tanibirumab used for cancer treatment, among others. The firm also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies.

Headquarters
Korea KR
IPO date
Nov 21, 2018
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
PharmAbcine Inc

Wall St Price Targets

Capital Returns

Buyback Yield
LOCKED
Debt Paydown Yield
LOCKED

Competitive Landscape